Arvinas Inc. (NASDAQ:ARVN), a biotechnology company specializing in protein degradation therapeutics, stands at a critical juncture as it approaches the release of pivotal clinical trial data.

One such example is using artificial intelligence technology and novel approaches in targeted protein degradation, which has the potential to transform the way medicinal chemistry and drug discovery ...

Herbicide development has slowed in recent years, but innovative research methods could soon drive significant progress in ...

They explore the possibilities of PROTAC targeted protein degrader technology, Richon talking through the example of cystic fibrosis and the role of proteins in longevity there – as well as the ...

Vepdegestrant is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER ...

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men. PrCa is marked by uncontrolled cellular growth that ...

Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of ...

Son of sevenless homolog 1 (SOS1) is an essential guanine nucleotide exchange factor (GEF) in KRAS-driven tumors, and it also functions as a downstream node protein of BCR-ABL, suggesting its critical ...

In silico analysis comparing over 150 SPiDEM degraders with the bromodomain-containing protein 4 (BRD4) PROTAC, dBET1, showed enhanced drug-likeness, highlighting the potential of SPiDEMs as orall ...

Shanghai Huilun Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 ...